Synthesis, characterization and systematic comparison of FITC-labelled GnRH-I, -II and -III analogues on various tumour cells

József Murányi, Pál Gyulavári, Attila Varga, Györgyi Bökönyi, Henriette Tanai, T. Vántus, Domonkos Pap, K. Ludányi, G. Mező, G. Kéri

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Targeted tumour therapy is the focus of recent cancer research. Gonadotropin-releasing hormone (GnRH) analogues are able to deliver anticancer agents selectively into tumour cells, which highly express GnRH receptors. However, the effectiveness of different analogues as targeting moiety in drug delivery systems is rarely compared, and the investigated types of cancer are also limited. Therefore, we prepared selectively labelled, fluorescent derivatives of GnRH-I, -II and -III analogues, which were successfully used for drug targeting. In this manuscript, we investigated these analogues' solubility, stability and passive membrane permeability and compared their cellular uptake by various cancer cells. We found that these labelled GnRH conjugates provide great detectability, without undesired cytotoxicity and passive membrane permeability. The introduced experiments with these conjugates proved their reliable tracking, quantification and comparison. Cellular uptake efficiency was studied on human breast, colon, pancreas and prostate cancer cells (MCF-7, HT-29, BxPC-3, LNCaP) and on dog kidney cells (Madin–Darby canine kidney). Each of the three conjugates was taken up by GnRH-I receptor-expressing cells, but the different cells preferred different analogues. Furthermore, we demonstrated for the first time the high cell surface expression of GnRH-I receptors and the effective cellular uptake of GnRH analogues on human pharynx tumour (Detroit-562) cells. In summary, our presented results detail that the introduced conjugates could be innovative tools for the examination of the GnRH-based drug delivery systems on various cells and offer novel information about these peptides.

Original languageEnglish
Pages (from-to)552-560
Number of pages9
JournalJournal of Peptide Science
DOIs
Publication statusPublished - Aug 1 2016

Fingerprint

Fluorescein-5-isothiocyanate
Gonadotropin-Releasing Hormone
Tumors
Cells
LHRH Receptors
Neoplasms
Drug Delivery Systems
Permeability
Membranes
Kidney
Cytotoxicity
MCF-7 Cells
Antineoplastic Agents
Pharynx
Pancreatic Neoplasms
Solubility
Colonic Neoplasms
Canidae
Prostatic Neoplasms
Derivatives

Keywords

  • conjugate
  • Detroit-562
  • FITC
  • GnRH
  • LHRH
  • pharynx tumour
  • targeted therapy

ASJC Scopus subject areas

  • Organic Chemistry
  • Drug Discovery
  • Pharmacology
  • Biochemistry
  • Molecular Biology
  • Molecular Medicine
  • Structural Biology

Cite this

Synthesis, characterization and systematic comparison of FITC-labelled GnRH-I, -II and -III analogues on various tumour cells. / Murányi, József; Gyulavári, Pál; Varga, Attila; Bökönyi, Györgyi; Tanai, Henriette; Vántus, T.; Pap, Domonkos; Ludányi, K.; Mező, G.; Kéri, G.

In: Journal of Peptide Science, 01.08.2016, p. 552-560.

Research output: Contribution to journalArticle

Murányi, József ; Gyulavári, Pál ; Varga, Attila ; Bökönyi, Györgyi ; Tanai, Henriette ; Vántus, T. ; Pap, Domonkos ; Ludányi, K. ; Mező, G. ; Kéri, G. / Synthesis, characterization and systematic comparison of FITC-labelled GnRH-I, -II and -III analogues on various tumour cells. In: Journal of Peptide Science. 2016 ; pp. 552-560.
@article{0c776586de344b2c94082c82094d8c90,
title = "Synthesis, characterization and systematic comparison of FITC-labelled GnRH-I, -II and -III analogues on various tumour cells",
abstract = "Targeted tumour therapy is the focus of recent cancer research. Gonadotropin-releasing hormone (GnRH) analogues are able to deliver anticancer agents selectively into tumour cells, which highly express GnRH receptors. However, the effectiveness of different analogues as targeting moiety in drug delivery systems is rarely compared, and the investigated types of cancer are also limited. Therefore, we prepared selectively labelled, fluorescent derivatives of GnRH-I, -II and -III analogues, which were successfully used for drug targeting. In this manuscript, we investigated these analogues' solubility, stability and passive membrane permeability and compared their cellular uptake by various cancer cells. We found that these labelled GnRH conjugates provide great detectability, without undesired cytotoxicity and passive membrane permeability. The introduced experiments with these conjugates proved their reliable tracking, quantification and comparison. Cellular uptake efficiency was studied on human breast, colon, pancreas and prostate cancer cells (MCF-7, HT-29, BxPC-3, LNCaP) and on dog kidney cells (Madin–Darby canine kidney). Each of the three conjugates was taken up by GnRH-I receptor-expressing cells, but the different cells preferred different analogues. Furthermore, we demonstrated for the first time the high cell surface expression of GnRH-I receptors and the effective cellular uptake of GnRH analogues on human pharynx tumour (Detroit-562) cells. In summary, our presented results detail that the introduced conjugates could be innovative tools for the examination of the GnRH-based drug delivery systems on various cells and offer novel information about these peptides.",
keywords = "conjugate, Detroit-562, FITC, GnRH, LHRH, pharynx tumour, targeted therapy",
author = "J{\'o}zsef Mur{\'a}nyi and P{\'a}l Gyulav{\'a}ri and Attila Varga and Gy{\"o}rgyi B{\"o}k{\"o}nyi and Henriette Tanai and T. V{\'a}ntus and Domonkos Pap and K. Lud{\'a}nyi and G. Mező and G. K{\'e}ri",
year = "2016",
month = "8",
day = "1",
doi = "10.1002/psc.2904",
language = "English",
pages = "552--560",
journal = "Journal of Peptide Science",
issn = "1075-2617",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Synthesis, characterization and systematic comparison of FITC-labelled GnRH-I, -II and -III analogues on various tumour cells

AU - Murányi, József

AU - Gyulavári, Pál

AU - Varga, Attila

AU - Bökönyi, Györgyi

AU - Tanai, Henriette

AU - Vántus, T.

AU - Pap, Domonkos

AU - Ludányi, K.

AU - Mező, G.

AU - Kéri, G.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Targeted tumour therapy is the focus of recent cancer research. Gonadotropin-releasing hormone (GnRH) analogues are able to deliver anticancer agents selectively into tumour cells, which highly express GnRH receptors. However, the effectiveness of different analogues as targeting moiety in drug delivery systems is rarely compared, and the investigated types of cancer are also limited. Therefore, we prepared selectively labelled, fluorescent derivatives of GnRH-I, -II and -III analogues, which were successfully used for drug targeting. In this manuscript, we investigated these analogues' solubility, stability and passive membrane permeability and compared their cellular uptake by various cancer cells. We found that these labelled GnRH conjugates provide great detectability, without undesired cytotoxicity and passive membrane permeability. The introduced experiments with these conjugates proved their reliable tracking, quantification and comparison. Cellular uptake efficiency was studied on human breast, colon, pancreas and prostate cancer cells (MCF-7, HT-29, BxPC-3, LNCaP) and on dog kidney cells (Madin–Darby canine kidney). Each of the three conjugates was taken up by GnRH-I receptor-expressing cells, but the different cells preferred different analogues. Furthermore, we demonstrated for the first time the high cell surface expression of GnRH-I receptors and the effective cellular uptake of GnRH analogues on human pharynx tumour (Detroit-562) cells. In summary, our presented results detail that the introduced conjugates could be innovative tools for the examination of the GnRH-based drug delivery systems on various cells and offer novel information about these peptides.

AB - Targeted tumour therapy is the focus of recent cancer research. Gonadotropin-releasing hormone (GnRH) analogues are able to deliver anticancer agents selectively into tumour cells, which highly express GnRH receptors. However, the effectiveness of different analogues as targeting moiety in drug delivery systems is rarely compared, and the investigated types of cancer are also limited. Therefore, we prepared selectively labelled, fluorescent derivatives of GnRH-I, -II and -III analogues, which were successfully used for drug targeting. In this manuscript, we investigated these analogues' solubility, stability and passive membrane permeability and compared their cellular uptake by various cancer cells. We found that these labelled GnRH conjugates provide great detectability, without undesired cytotoxicity and passive membrane permeability. The introduced experiments with these conjugates proved their reliable tracking, quantification and comparison. Cellular uptake efficiency was studied on human breast, colon, pancreas and prostate cancer cells (MCF-7, HT-29, BxPC-3, LNCaP) and on dog kidney cells (Madin–Darby canine kidney). Each of the three conjugates was taken up by GnRH-I receptor-expressing cells, but the different cells preferred different analogues. Furthermore, we demonstrated for the first time the high cell surface expression of GnRH-I receptors and the effective cellular uptake of GnRH analogues on human pharynx tumour (Detroit-562) cells. In summary, our presented results detail that the introduced conjugates could be innovative tools for the examination of the GnRH-based drug delivery systems on various cells and offer novel information about these peptides.

KW - conjugate

KW - Detroit-562

KW - FITC

KW - GnRH

KW - LHRH

KW - pharynx tumour

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84979037359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979037359&partnerID=8YFLogxK

U2 - 10.1002/psc.2904

DO - 10.1002/psc.2904

M3 - Article

SP - 552

EP - 560

JO - Journal of Peptide Science

JF - Journal of Peptide Science

SN - 1075-2617

ER -